Similar results were found in another Chinese study by Bai et al., retrospectively analyzing 28 patients with BRAF-V600E-mutant ALM who were treated with either vemurafenib, sorafenib, or BGB-283. This evidence concerns the gene BRAF and acral lentiginous melanoma.